NRx Pharmaceuticals (NRXP) Proxy Filing summary

Executive summary

• Annual meeting scheduled for March 23, 2026, to be held virtually at 10:00 a.m. Eastern Time.

• Proxy materials, including the Proxy Statement and Annual Report, are available online for shareholder review.

• A supplement was issued to correct proposal numbering errors on the proxy card and cover letter; all other information remains unchanged.

Voting matters and shareholder proposals

• Election of Chaim Hurvitz and Michael Taylor as Class I directors to serve until the 2028 annual meeting.

• Approval of an amendment to the 2021 Omnibus Incentive Plan.

• Ratification of Weinberg & Company, P.A. as independent auditors for the fiscal year ending December 31, 2025.

• Non-binding advisory vote on the compensation of named executive officers.

• Board recommends voting “For” all proposals.

Board of directors and corporate governance

• Board nominees for Class I directors are Chaim Hurvitz and Michael Taylor.

• Directors, if elected, will serve until the 2028 annual meeting or until successors are appointed and qualified.